Combination of il-12 and ox40l for cancer immunotherapy
AssigneeWuhan Houxian Biopharmaceutical Co. Ltd.
InventorsHongbing SHU, Mingming HU, Shu LI, Mi LI, Qing YANG
Life of this patent
Estimating the term…
Loading patent…
AssigneeWuhan Houxian Biopharmaceutical Co. Ltd.
InventorsHongbing SHU, Mingming HU, Shu LI, Mi LI, Qing YANG
Estimating the term…
Provided are compositions and methods for treating cancers. It is demonstrated herein that mRNA molecules expressing an OX40 agonist protein and the IL-12 protein, when used in combination, achieve synergistic anti-tumor effects. Such synergistic effect is further enhanced when a soluble portion of the OX40 ligand (OX40L) is used as the agonist, instead of the full-length OX40L protein. The mRNA molecules are preferably synthetic and packaged in lipid nanoparticles for delivery. Whether delivered through intratumoral injections or injected by other routes, these mRNA molecules can effectively inhibit tumor growth at local as well as distal sites. In addition, with the increased anti-tumor efficacy, the combinations, in particular at a mass ratio of IL-12 to OX40L between 1:1 and 1:3, are associated with reduced toxicity. Interestingly, when GM-CSF is further added to the combination, the anti-tumor effects are further improved.
A method for treating cancer in a patient, comprising administering to the patient a first mRNA encoding an OX40 agonist, and a second mRNA encoding IL-12, wherein the OX40 agonist is an OX40 ligand (OX40L), a polypeptide comprising the extracellular domain of OX40L, or an agonist anti-OX40 antibody or antigen-binding fragment thereof.
18-20. (canceled)
22-23. (canceled)
A method for treating cancer in a patient, comprising administering to the patient a first agent comprising a mRNA encoding IL-12, and a second agent comprising an OX40 agonist, wherein the OX40 agonist is an agonist anti-OX40 antibody or antigen-binding fragment thereof, an OX40 ligand (OX40L), or a polypeptide comprising the extracellular domain of OX40L.
25-46. (canceled)
A pharmaceutical composition comprising a first agent comprising a mRNA encoding IL-12, and a second agent comprising an OX40 agonist, wherein the OX40 agonist is an agonist anti-OX40 antibody or antigen-binding fragment thereof, an OX40 ligand (OX40L), or a polypeptide comprising the extracellular domain of OX40L.
Dependencies are inferred from the claim text.